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Abstract
Purpose: We designed a gene profiling experiment to identify genes involved in secondary drug resistance in mantle
cell lymphomas (MCL).
Experimental Design: We obtained paired tissue samples collected from the same patients before treatment and
after relapse or progression. Variations in gene expression between the 2 samples were estimated for 5 patients. For
each gene, the mean variation was estimated for patients with a refractory primary tumor and for responders who
developed secondary drug resistance. Nine genes of interest were selected on the basis of the magnitude and
statistical significance of the variation of expression in responders and non-responders.
Results: BMP7 was the only one with significantly increased expression at relapse in patients who developed
secondary resistance. Validation of BMP7 as a key gene involved in secondary resistance was performed using
cultures of cell line. Incubation of BMP7 with MCL cell lines increased their resistance to bortezomib and cytarabine,
while inhibition of BMP7 expression by siRNA correlated with increased cell death linked to drug application.
Conclusion: Variations in gene expression after treatment point out BMP7 as a key gene involved in secondary
resistance in mantle cell lymphoma.
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Introduction
Mantle cell lymphoma is a rare lymphoma entity which is
usually incurable with available therapies. Despite a high rate
of response to 1st-line immuno-chemotherapy, the probability of
cure is low and the median survival about 5 years [1]. In
patients who achieve a primary response to therapy, secondary
drug resistance almost invariably develops [2,3]. Identification
of mechanisms involved in secondary drug resistance is a
major challenge in MCL. The biological effects of therapy on
tumor cells is an area of intense research in oncology.
Microarray analyses offer the opportunity to identify genes that
may be deregulated during tumor progression or after
anticancer therapy. The current strategy of gene profiling is
based on the use of tumor samples obtained exclusively before
treatment. The objective of this strategy is to find genes or
combinations of genes likely to predict the effect of treatment.
Unfortunately, this strategy leads to unstable results and to
poor quality predictions [4]. To overcome these problems, one
solution is to increase the size of the studies; the price for
credibility being the inclusion of tens or hundreds of patients.
This solution is not well suited to rare pathologies. Moreover
and paradoxically, the idea of using large series of patients
may be justified only when the objective is to demonstrate that
small difference between two groups are statistically significant,
but may not be relevant for the development of an individual
patient-oriented therapy. At the individual patient level small
differences in gene expression have slim chances of being
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biologically relevant and clinically useful. This is why we focus
on changes in gene expression (instead of pretreatment gene
expression levels) that are large enough to be potentially
biologically relevant and could be used as biomarkers at
individual patient level (instead of being statistically significant
in large groups of patients). We looked at changes in gene
expression using paired tissue samples collected from the
same patient, one sample taken before and the other after
relapse or progression. We assumed that the variation in gene
expression between the two samples from the same patient
reflected modifications that occurred during tumor progression
and could reveal new biological mechanisms of drug
resistance. The findings observed through this strategy were
further investigated using cell lines.
Materials and Methods.
Patients
Nineteen patients participated in the study. This study was
approved by Institut gustave Roussy IRB, and data were
analyzed anonymously. Paired frozen tissue samples were
obtained from 12 patients and formalin-fixed and paraffin
embedded (FFPE) tissue samples from seven other patients
(Table 1).
Tissue samples
All patients had 2 samples collected from the same tissue
(blood or lymph nodes). One sample was collected before
treatment and the second was collected at the time of relapse
for patients who had initially responded to the treatment and
subsequently developed secondary resistant disease, or at the
end of initial therapy when the lymphoma was considered
refractory to treatment (at least 4 weeks after the last
chemotherapy).
Microarray analysis
Microarrays were processed when both the pretreatment and
the post-treatment tissue sample had an adequate quality of
RNA. We used Agilent long (60 bp) oligonucleotide microarrays
and the dual color analysis method in which probes from two
specimens are differentially labeled by incorporating Cyanine 5
and Cyanine 3, respectively. For each patient, the paired
sample (before treatment and at relapse/progression) was co-
hybridized on Agilent dual color DNA chips.
The results of the microarray analysis have been deposited
on array-express (http://www.ebi.ac.uk/arrayexpress/,
Experiment name: IGR_CamaraClayette_MCL; ArrayExpress
accession: E-MTAB-1090); the details for journal/reviewer
access are Username: Reviewer_E-MTAB-1090; and
Password: ULK4aVie.
Table 1. Patient characteristics; Tissue samples were collected from Patients 1 to 12 for microarray analyzes; the quality of
one or 2 of the samples was insufficient for patients 6 to 12.
# Gender age LDH Stage Treatment response Tissue origin:
Pre-treatment
sample
Post-treatment
sample
1 M 74 N IV CLB Yes Lymph-node OK OK
2 F 56 >N IV DHAP-R yes blood OK OK
3 M 73 N IV CHOP No Lymph-node OK OK
4 M 73 >N IV DHAP-R yes blood OK OK
5 M 63 N IV CLB No blood OK OK
6 M      lymph node Quality pb OK
7 M      lymph node Quality pb Quality pb
8 M      lymph node Quality pb Quality pb
9 M      Lymph node Quality pb Quality pb
10 M      blood Quality pb Quality pb
11 F      Blood Quality pb OK
12 F      blood OK Quality pb
13 M 50 N IV CHOP No Lymph-node OK OK
14 F 60 N III CHOP yes Lymph-node OK OK
15 M 58 >N IV CHOP-DHAP yes Lymph-node OK OK
16 M 63 N IV CHOP No Lymph-node OK OK
17 M 43 N II CHOP No Lymph-node OK OK
18 M 48 N IV CHOP yes Lymph-node OK OK
19 M 54 ND IV CHOP No Lymph-node OK OK
Formalin-fixed and paraffin embedded (FFPE) samples were collected from patients 13 to 19 for immunohistochemical studies.
LDH: Lactate deshydrogenase; N: normal is good prognostic factor, >N is poor prognosis factor
Quality pb: inadequate quality
ND: not done
doi: 10.1371/journal.pone.0073993.t001
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Cell culture
Jeko human lymphoma cell lines were cultured in RPMI 1640
medium and UPN1 human lymphoma cell lines were grown in
alpha-MEM (Invitrogen, France).
Bisulfite DNA treatment and sequencing
Genomic DNA was isolated from MCL cell lines using
QIAGEN’s standard procedures. The converted BMP7
promoter was identified by PCR with converted primers:
forward (5′-GGATTTTTAGGTTTGTTGGTTG-3′) and reverse
(5′ CAACTCACAATAAACACACATACAT-3′).
Immunohistochemistry
Immunohistochemical studies of BMP7 were performed on
surgical specimens from patients with Mantle Cell Lymphoma
using the avidin–biotin–peroxidase method (Quick kit, Vector
Laboratories, USA) on formalin-fixed, paraffin-embedded tissue
sections (4 µm). The mouse monoclonal antibody directed
against human BMP7 (R&D Systems, Inc., Minneapolis, MN ;
Ref : MAB3542 ; clone 164313) was used at 25 µg/mL (1:40).
SiRNA transfections and chemotherapy
The following double-stranded RNA 21 base pair
oligonucleotides (Qiagen S.A, Courtaboeuf, France) were
used: BMP7-3: 5’ CAA UGA ACA AGA UCC UAC A dTdT 3’
and 5’ UGU AGG AUC UUG UUC AUU G dGdA 5’ BMP7-4: 5’
CGG AAG UUC CUG UAA UAA A dTdT3’ and 5’ UUU AUU
ACA GGA ACU UCC G dGdG 5’. Transfections were
performed using 4 µl of lipofectamine 2000 (Invitrogen, France)
incubated 10 minutes in a total volume of 100 µl of serum-free
Opti-Mem. Chemotherapy was added to the medium 24 or 48
hours post-transfection over 24 hours. Cytarabine and
Bortezomib were dissolved according to the manufacturer’s
instructions before adding 20 µg/ml and 5 ng/ml respectively to
cell culture media.
Statistical analysis of microarray data.
Each gene was analyzed independently of the others. The
main analysis was based on expression log-ratios, which were
defined as the natural logarithm of the ratio between the
expression measured in the sample obtained after treatment
and the expression in the sample collected before treatment
from the same patient.
Results
Paired frozen tissue samples were obtained from 12
patients. The RNA quality was sufficient for microarray
analyses for only 5 out of the 12 patients initially screened for
the microarray analyses (Table 1). Of the 5 patients with both
RNA samples eligible for the analyses (one collected before
treatment and one after treatment), 3 were initially sensitive to
chemotherapy and relapsed after developing secondary
resistance (secondary resistant tumor) and 2 had a refractory
primary disease and did not respond to their first treatment
(non-responders).
Gene expression fold change was defined as the ratio
between the expression after therapy and at diagnosis. For
each patient, the paired sample (before treatment and at
relapse/progression) was co-hybridized on Agilent dual color
DNA chips. The main analysis focused on the ratio between
gene expression fold change in initially sensitive (secondary
resistant tumor) and primary refractory tumors (non-
responders) or fold change ratio (FCR). Nine genes with an
absolute FCR value greater than 2 and a P value <0.01 were
considered relevant (Table 2). BMP7 expression, which was
very low before treatment in all patient’s samples whatever the
clinical response, was multiplied by 7.31 after relapse in
secondary resistant tumors, but did not vary significantly in
non-responders (Figure 1). This represents the largest absolute
FCR value of the 9 relevant genes (FCR=6.96; P=0.002). Most
of the other relevant genes had significantly decreased
expression at relapse in secondary resistant tumors and/or
increased expression in non-responders. Because BMP7 had
an increased expression at relapse in secondary resistant
tumors, we investigated the putative role of BMP7 in secondary
resistance.
Expression of BMP7 at relapse in MCL patients initially
sensitive to chemotherapy
The presence of BMP7 mRNA in the samples of the 5 MCL
patients tested on Agilent DNA chips was verified with RT-PCR
analyses. BMP7 was detectable only in the 3 samples obtained
at the time of relapse in secondary resistant tumors; it was not
detectable in the samples obtained before treatment whatever
the response to initial therapy, nor in the samples obtained at
relapse in refractory primary tumors (Figure 2A).
We also assessed whether the BMP7 protein could be
detected by immunohistochemistry on paraffin embedded
tissues in MCL cases (none of these cases had frozen samples
for PCR analysis). Seven paired samples collected at diagnosis
and after first-line therapy (patients 13 to 19, Table 1) that were
not included in the Agilent DNA chips assays were
investigated: 3 secondary resistant tumors (initially sensitive)
and 4 refractory primaries diseases (non responders). None of
these 7 patient samples expressed BMP7 at diagnosis, 2 out of
3 secondary resistant samples expressed detectable BMP7 at
relapse (see Figure 2B that represent one of the two BMP7-
positive patient at relapse), and none of the 4 refractory
primary tumors expressed BMP7 during the refractory phase of
the disease
Overall, of the 12 MCL samples analyzed at diagnosis, none
had BMP7 expression detectable by gene array or IHC
analysis. Out of the 6 initially sensitive patients, 5/6 tumor
samples collected after treatment had an increase of BMP7
expression. None of the 6 samples collected from non-
responders patients after treatment expressed BMP7.
BMP7 expression in MCL cell lines
To test the hypothesis that BMP7 was supposedly a
biological factor capable of protecting MCL cells against
chemotherapy, we investigated with RT-PCR analysis whether
BMP7 mRNA was detectable in four MCL cell lines (UPN1,
Jeko, Rec-1 and GRANTA-519). Jeko expressed BMP7
BMP7 and Lymphoma
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mRNA, but the other cell lines tested did not (UPN1, Rec-1 and
GRANTA-519) (Figure 3A). We used an Elisa assay to
investigate whether Jeko cells were able to secrete BMP7.
BMP7 was detectable in the supernatant of Jeko cells at a
concentration exceeding 10 pg/ml on day 7 of culture in serum-
free Opti-Mem medium, whereas no BMP7 was detected in
medium alone (optical density lower than the negative control
of the scale) as well as in the supernatant from UPN1 on days
2 and 7, or Jeko on day 2.
Table 2. Characteristics of the genes with a relevant fold change ratio (FCR).
Short name / Description Expression ratio in non-responders (A) Expression ratio in responders (B) Fold Change Ratio FCR(*)
 Value P value Value P value Value P value
BMP7
Bone
morphogenetic
protein 7, regulates
cell proliferation,
cell differentiation,
apoptosis,
folliculogenesis,
ovulation, and
bone formation,
may play roles in
skeletal and
nervous system
development,
preserves kidney
function after acute
renal failure
1.05 0.76 7.31 0.0005 6.96 0.002
EGR3
Early growth
response 3,
member of the Egr
family of immediate
early transcription
factors, induced by
light in the
suprachiasmatic
nucleus (SCN);
deletion of murine
Egr3 results in
higher perinatal
mortality and
multiple muscle
development
disorders
2.54 0.002 0.56 0.005 -4.53 0.001
BCL2A1
BCL2-related
protein, a member
of the Bcl-2 family
of apoptosis
regulators; inhibits
apoptosis,
promotes
tumorigenesis, and
may play a
protective role
during
inflammation
2.21 0.005 0.60 0.009 -3.72 0.002
I_1000049 Protein of unknownfunction 0.54 0.009 1.30 0.05 2.39 0.007
BMP7 and Lymphoma
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Since BMP7 mRNA expression was different between the
MCL cell lines, we investigated the methylation profile of the
BMP7 promoter CpG islands in the four MCL cell lines. The
BMP7 promoter was found to be hypermethylated in UPN1,
Rec-1 and GRANTA-519 cell lines but was demethylated in the
Jeko cell line (Figure 3B).
Protective effect of BMP7 inexcess against Bortezomib
on Jeko cells
The BMP7 effect on cell survival was measured after 2 days
incubation in the presence of BMP7 in excess (200 ng/ml).
BMP7 in excess had an apoptotic effect on UPN1 cell line: the
proportion of annexin V-positive cells was 14% in serum-free
media and 74% in the presence of BMP7 (four independent
experiments in triplicate P<10-4). No effect of BMP7 in excess
was found on Jeko, Rec-1 and GRANTA-519 survival, even
Table 2 (continued).
Short name / Description Expression ratio in non-responders (A) Expression ratio in responders (B) Fold Change Ratio FCR(*)
 Value P value Value P value Value P value
TBX21
Protein with strong
similarity to T-box
21 (mouse Tbx21),
which is a
transcription factor
that likely regulates
differentiation of
helper T-cells into
Th1 cells, contains
a T-box domain,
which bind DNA
1.45 0.03 0.60 0.008 -2.39 0.007
TRAF5
TNF receptor-
associated factor
5, member of a
family of proteins
that interact with
the cytoplasmic
domain of
oligomerized TNF
receptors, binds
CD40 (TNFRSF5)
and mediates
signaling through
activation of NF-
kappaB and JNK
pathways
0.44 0.002 1.03 0.66 2.33 0.004
CCL28
Homo sapiens
chemokine (C-C
motif) ligand 28
(CCL28), transcript
variant 2, mRNA
2.02 0.0005 0.97 0.39 -2.09 0.001
RAB11-FIP4
Protein with
moderate similarity
to human Rab11-
FIP3, which
functions in
vesicle-mediated
transport
1.33 0.05 0.64 0.009 -2.07 0.008
MGC4189 Protein of unknownfunction 1.83 0.001 0.92 0.02 -2.00 0.002
FCR is estimated as B/A. When the ratio is less than 1, FCR value is given as – A/B. The table is sorted according to the absolute value of FCR.
doi: 10.1371/journal.pone.0073993.t002
BMP7 and Lymphoma
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when exposure was extended to 7 days (Figure 3C). We
assessed whether BMP7 had a protective effect against
Bortezomib cytotoxicity on BMP7-expressing Jeko cell lines.
Jeko cells were cultured with BMP7 (200 ng/ml) or in free
media conditions. Jeko cells treated with Bortezomib plus
BMP7 had a lower apoptotic cell rate when compared to the
same cells cultured in the same conditions but without BMP7
(four independent experiments in triplicate; P=0.002, Mann
Withney test; data not shown)
Effect of BMP7 mRNA inhibition on Bortezomib and
Cytarabine cytotoxicity
Jeko cells were transfected using a transient transfection
assay with two BMP7 siRNAs (BMP7-4 and BMP7-3) or a
nonsilencing siRNA as a control. At 48h and 72h post
transfection with BMP7-4 siRNA, the mRNA levels of BMP-7
were reduced by 55 and 57% respectively and the expression
of the protein at 72 hours (Figure 4). No direct effect on cell
survival was observed neither with the BMP-7 siRNA nor with
the nonsilencing siRNA at 48h and 72h after cell transfection.
We next treated Jeko cells 24h or 48h after transfection with
either Bortezomib (5 ng/ml) or Cytarabine (20 µg/ml) for 24 h.
Drugs were given at their IC50 concentration on Jeko cells
(data not shown). Apoptotic cells were quantified 48h and 72h
Figure 1.  Gene expression ratios were calculated for each
gene in primary refractory (non-responders) and in
responders (secondary resistant).  Gene expression ratio is
equal to the geometric mean gene expression after treatment
divided by the geometric mean gene expression before
treatment. Gene expression ratios greater than one correspond
to increased expression after treatment and conversely. Each
point on the figure corresponds to a gene expression ratio in
responders according to the expression ratio in non-
responders. Nine genes classified as relevant (see methods)
are symbolized by black dots. BMP7 which was selected for
further investigations is symbolized by a red dot. Small grey
symbols were used for “Other genes”.
doi: 10.1371/journal.pone.0073993.g001
after transfection. Cytarabine and Bortezomib induced
apoptosis in approximately 66% and 60% of cells (measured
as annexin V- and PI-positive cells) at 48h respectively. When
cells were transfected with BMP7 siRNA, the proportion of
apoptotic dead cells (annexin V- and 7-AAD-positive cells) was
markedly increased (from 8.3% to 31.5%; P = 0.002) when
exposed to Bortezomib at 5 ng/ml. This increased apoptotic
rate was also associated with a decreased number of viable
cells (Figure 4). The same experiments were performed with
the BMP7-3 siRNA with similar results (data not shown).
Discussion
Using tissue from the same patient’s tumor collected at
different phases of the disease is an attractive option since the
internal control for gene array analysis is achieved with the
same tumor. The sample at diagnosis is collected from the
same patient as the sample analyzed at relapse or at the
refractory phase of the disease. Our approach is based on the
analysis of gene expression changes that occurred between
initial treatment and relapse, when secondary resistance
developed. We arbitrarily chose to exclusively select and
Figure 2.  Expression of BMP7 in MCL lymphoma
cells.  Figure 2A: from patients tested by DNA chips, RT-PCR
was performed in two independent experiments before therapy
(lane 1, 3, 5, 7 and 9) and after therapy (lane 2, 4, 6, 8 and 10).
Patient 1 (lanes 1 and 2), patient 2 (lanes 3 and 4), patient 3
(lanes 5 and 6), patient 4 (lane7 and 8) patient 5 (lanes 9 and
10). Patients 1, 2 and 4 were initially sensitive to chemotherapy
(secondary resistant tumors). Human placenta was used as a
positive control (lane 11) and mix without cDNA as negative
control (lane 12). BMP7 was expressed in the 3 patients at
relapse, but was not expressed in the 2 patients with refractory
disease at diagnosis and after having failed on therapy.
ß2microglobuline probe was used as internal reference. Figure
2B: Immunohistochemical analysis of one of the 2 patient’s
tumor at diagnosis and at relapse, that expressed BMP7 at
relapse (secondary resistant lymphoma).
doi: 10.1371/journal.pone.0073993.g002
BMP7 and Lymphoma
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e73993
investigate genes with at least a two-fold change in their
expression. We identified BMP7 based on data from a limited
number of patients assessed at different time points during
their treatment, using very stringent gene selection criteria. We
then used cell lines to validate the results. BMP7 was the only
gene with a relevant increase in expression at relapse, but not
in refractory cases. Our studies on cell lines are consistent with
better resistance of BMP7-positive cell lines to cytotoxic agents
or targeted therapy. The limited number of patients is a
drawback essentially due to working on a rare and molecularly
well-defined pathology, but also on collection of two
independent biopsies with a good quality mRNA sampling from
the same patient. Even in the case of reaching high quality
samples for gene array analysis in 80% of biopsies, requiring
two biopsies from the same patient decrease this probability to
Figure 3.  A: Expression of mRNAs encoding BMP7 tested
by RT-PCR performed on 1: UPN1, 2: Jeko, 3: Rec-1, 4:
GRANTA-519 and 5: placenta (positive control).  B:
methylation profile of BMP-7 CpG islands in the cell line C:
UPN1, Jeko, Rec-1 and GRANTA-519 cells were cultured in
serum-free media in the presence or absence of 200 ng/ml of
BMP-7 for 7 days. BMP-7 had no effect on Jeko, GRANTA-519
and Rec-1 cell survival and on annexin V-positive cells
compared to serum-free media alone.
doi: 10.1371/journal.pone.0073993.g003
about 60% [5]. However, we consider that dealing with small
sample sizes is a mandatory step on the road to personalized
medicine, where every patient is expected to gain access to
personalized treatment. This is contrary to what is done in most
(past and present) profiling studies performed on
heterogeneous pathologies and in which the possibility of a
unique molecular mechanism is improbable. The strategy we
used in this work differs with classic gene expression profiling
in at least 3 respects: patients were used as their own controls;
gene selection was performed at the patient’s level and
considered relevant when it was found in other patient’s
samples collected in the same clinical situation, and findings
were ultimately validated biologically.
Of the different genes selected with this strategy, BMP7 was
the only gene that was expressed only at relapse and in
patients who initially responded to therapy. Our findings
suggested that BMP-7 could be a gene involved in secondary
drug resistance in these mantle cell lymphomas. To our
knowledge, no other studies focused on a potentially protective
effect of BMP7 in cancer cells in stressed conditions have been
reported. We found that BMP7 down regulation in Jeko cells
was able to increase anticancer drug sensitivity. Furthermore,
Figure 4.  SiRNA BMP7 had a negative effect on cell
survival at all time points assessed with both drugs
showing that BMP7 plays a role in drug resistance.  Jeko
cells were exposed with Bortezomib (5 ng/ml) or Cytarabine
(20 µg/ml) 24h or 48h after transfection with a BMP7 siRNA or
a nonsilencing siRNA used as a control (see material and
methods). BMP7 protein expression was assessed by
immunoblotting analyzes. Annexin V- and PI-negative cells
(non apoptotic) were quantified 48h and 72h after transfection.
BMP7 siRNA markedly increased the fraction of annexin V-
and PI-negative cells showing that BMP7 suppression plays a
role in Jeko cell chemosensitivity to Bortezomib and
Cytarabine.
doi: 10.1371/journal.pone.0073993.g004
BMP7 and Lymphoma
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an excess of BMP7 had a protective effect when the same cells
were treated with cytarabine or bortezomib.
This is the 1st time that BMP7 is identified as a candidate
gene that might play a role in secondary drug resistance. Little
is known about the role of BMP7 in oncology, especially in drug
resistance. BMP proteins (BMPs) are secreted signaling
molecules that belong to the transforming growth factor
superfamily [6]. BMP7 signaling is elicited through specific
serine/threonine kinase receptors. Initially, BMP7 interacts with
BMP receptor R2 which subsequently binds to BMP receptor
R1. This BMP R1-R2 dimerization induces activation of the
canonical BMP pathway through smad 1, 5 and 8
phosphorylation which forms heteromeric complexes with the
common mediator smad 4. Activated smad complexes then
translocate into the nucleus and bind to DNA consensus smad
binding sites and directly regulate the expression of different
target genes [7–9]. Like many other RTK, the activated BMP
receptor complex is now known to activate alternative
pathways independently of the Smad signaling pathway. These
alternative effects include activation of the phosphoinositol-3
kinase (PI3K) through PTEN inhibition and activation of
mitogen activated protein kinases (MAPK) through extracellular
signal regulated kinase (ERK), c-jun N-terminal kinase (JNK),
and p38 [10–12]. The role of BMP7 in oncogenic processes
was recently investigated in various tumor models [12–18]. To
our knowledge, no other study has reported on the role of
BMP7 in primary or secondary drug resistance, and recent
studies shown that BMP7 was the most frequently express
BMP protein in lymphoma cells and in normal germinal center
B-cells [19]. Nevertheless, in multiple myeloma BMP6 was
found to protect cells against bortezomib-induced apoptosis
[20]. Although BMP7 induce apoptosis in normal B-cells, B-cell
lymphoma cells can escape BMP-induced inhibition of cell
growth suggesting an autocrine growth regulation and that
malignant cells can escape autocrine growth inhibitory effect of
BMP7 [19,21]. However, in these studies, the role of BMP7 in
secondary drug resistance was not explored. BMP7 expression
was found to be associated with tumor progression and the
occurrence of metastasis in malignant melanomas and in
colonic carcinoma [15,22]. The effect of BMP7 on cell survival
has been studied essentially in prostatic tumors. In the C4-2B
prostatic cancer cells, BMP7 is able to promote cell survival by
inhibiting stress-induced apoptosis in culture-free medium
conditions via both the smad/survivin and c-jun NH2-terminal
kinase pathway putatively through survivin overexpression [12].
We found that there was a relation between promoter
hypermethylation and BMP7 mRNA expression in MCL cell
lines. The same epigenetic regulation of BMP7 was also
observed in prostatic and gastric cancers where BMP7
expression is associated with a more aggressive phenotype
[14,23,24].
In conclusion, secondary drug resistance could be the result
of different processes and remain an important question in
oncology. One hypothesis in MCL could be that, before
therapy, BMP7-positive cells had a proliferation disadvantage
compared to BMP7-negative cells that compose the majority of
tumor cells, and would be undetectable but present in the MCL.
In initially chemo sensitive cases, active chemotherapeutic
agents kill the BMP-7 negative cells, leading to the persistence
of selected BMP7-positive cells that are more prone to resist to
chemotherapy. At relapse, these BMP7-positive cells may
represent the majority of tumor cells and became detectable. In
primary chemoresistant lymphoma, these cells remained
undetectable. This could probably explain why BMP7 was not
detectable in the majority of lymphoma cells from patients with
primary resistant MCL (before treatment and at the time of
progression). This strategy is not adapted to identify relevant
biological targets of refractoriness in primary refractory cases
where no major modification is observed in the tumor over time
(when we compare the tumor at diagnosis and in the refractory
phase after one line of chemotherapy as it was the case in this
study). We are able to identify modification that appears in the
tumor where chemotherapy is able to induce major reduction of
tumor burden. Our results suggest that with a simple and
sequential gene array evaluation of tumors, new genes of
interest can be identified in a few, but well characterized and
homogeneous groups of tumors.
Supporting Information
File S1.  Supporting materials and methods.
(DOC)
Acknowledgements
The authors thank Lorna Saint Ange for editing.
Author Contributions
Conceived and designed the experiments: SK VC VR.
Performed the experiments: VC SK SR TL TF JB MB VL GL
VR. Analyzed the data: SK VC VR. Contributed reagents/
materials/analysis tools: SK VC SR VR. Wrote the manuscript:
SK VC JB VL VR.
References
1. Ghielmini M, Zucca E (2009) How I treat mantle cell lymphoma. Blood
114: 1469-1476. doi:10.1182/blood-2009-02-179739. PubMed:
19556426.
2. Goy A, Kahl B (2011) Mantle cell lymphoma: the promise of new
treatment options. Crit Rev Oncol/Hematol 80: 69-86. doi:10.1016/
j.critrevonc.2010.09.003. PubMed: 21168343.
3. Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M et al.
(2009) Mantle cell lymphoma: biological insights and treatment
advances. Clin Lymphoma Myeloma 9: 267-277. doi:10.3816/CLM.
2009.n.055. PubMed: 19717376.
4. Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome
with microarrays: a multiple random validation strategy. Lancet 365:
488-492. doi:10.1016/S0140-6736(05)17866-0. PubMed: 15705458.
5. Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F et
al. (2012) Sequential research-related biopsies in phase I trials:
acceptance, feasibility and safety. Ann Oncol 23: 1301-1306. doi:
10.1093/annonc/mdr383. PubMed: 21917737.
6. Hogan BL (1996) Bone morphogenetic proteins in development. Curr
Opin Genet Dev 6: 432-438. doi:10.1016/S0959-437X(96)80064-5.
PubMed: 8791534.
BMP7 and Lymphoma
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e73993
7. Miyazono K, Maeda S, Imamura T (2005) BMP receptor signaling:
transcriptional targets, regulation of signals, and signaling cross-talk.
Cytokine Growth Factor Rev 16: 251-263. doi:10.1016/j.cytogfr.
2005.01.009. PubMed: 15871923.
8. Tamaki K, Souchelnytskyi S, Itoh S, Nakao A, Sampath K et al. (1998)
Intracellular signaling of osteogenic protein-1 through Smad5
activation. J Cell Physiol 177: 355-363. doi:10.1002/
(SICI)1097-4652(199811)177:2. PubMed: 9766532.
9. Zwijsen A, Verschueren K, Huylebroeck D (2003) New intracellular
components of bone morphogenetic protein/Smad signaling cascades.
FEBS Lett 546: 133-139. doi:10.1016/S0014-5793(03)00566-0.
PubMed: 12829249.
10. Beck SE, Carethers JM (2007) BMP suppresses PTEN expression via
RAS/ERK signaling. Cancer Biol Ther 6: 1313-1317. PubMed:
18059158.
11. Hu MC, Wasserman D, Hartwig S, Rosenblum ND (2004) p38MAPK
acts in the BMP7-dependent stimulatory pathway during epithelial cell
morphogenesis and is regulated by Smad1. J Biol Chem 279:
12051-12059. PubMed: 14718543.
12. Yang S, Lim M, Pham LK, Kendall SE, Reddi AH et al. (2006) Bone
morphogenetic protein 7 protects prostate cancer cells from stress-
induced apoptosis via both Smad and c-Jun NH2-terminal kinase
pathways. Cancer Res 66: 4285-4290. doi:
10.1158/0008-5472.CAN-05-4456. PubMed: 16618753.
13. Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R et al.
(2009) BMP7 influences proliferation, migration, and invasion of breast
cancer cells. Cancer Lett 275: 35-43. doi:10.1016/j.canlet.2008.09.028.
PubMed: 18980801.
14. Aoki M, Ishigami S, Uenosono Y, Arigami T, Uchikado Y et al. (2011)
Expression of BMP-7 in human gastric cancer and its clinical
significance. Br J Cancer 104: 714-718. doi:10.1038/sj.bjc.6606075.
PubMed: 21224856.
15. Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H et al. (2008)
Clinical significance of BMP7 in human colorectal cancer. Ann Surg
Oncol 15: 1530-1537. doi:10.1245/s10434-007-9746-4. PubMed:
18259822.
16. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M et al. (2005)
Bone morphogenic proteins are overexpressed in malignant melanoma
and promote cell invasion and migration. Cancer Res 65: 448-456.
PubMed: 15695386.
17. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG et al. (2006)
Expression profiling identifies altered expression of genes that
contribute to the inhibition of transforming growth factor-beta signaling
in ovarian cancer. Cancer Res 66: 8404-8412. doi:
10.1158/0008-5472.CAN-06-0683. PubMed: 16951150.
18. Yang S, Pham LK, Liao CP, Frenkel B, Reddi AH et al. (2008) A novel
bone morphogenetic protein signaling in heterotypic cell interactions in
prostate cancer. Cancer Res 68: 198-205. doi:
10.1158/0008-5472.CAN-07-5074. PubMed: 18172312.
19. Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI et al. (2012)
Role of Smad proteins in resistance to BMP-induced growth inhibition
in B-cell lymphoma. PLOS ONE 7: e46117. doi:10.1371/journal.pone.
0046117. PubMed: 23049692.
20. Grcević D, Kusec R, Kovacić N, Lukić A, Lukić IK et al. (2010) Bone
morphogenetic proteins and receptors are over-expressed in bone-
marrow cells of multiple myeloma patients and support myeloma cells
by inducing ID genes. Leuk Res 34: 742-751. doi:10.1016/j.leukres.
2009.10.016. PubMed: 19926132.
21. Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI et al. (2011)
Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig
production in human B cells: differential effects of BMP-6 and BMP-7.
Eur J Immunol 41: 3135-3145. doi:10.1002/eji.201141558. PubMed:
21898381.
22. Rothhammer T, Wild PJ, Meyer S, Bataille F, Pauer A et al. (2007)
Bone morphogenetic protein 7 (BMP7) expression is a potential novel
prognostic marker for recurrence in patients with primary melanoma.
Cancer Biomark 3: 111-117. PubMed: 17522432.
23. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H et al. (2009)
Discovery of novel hypermethylated genes in prostate cancer using
genomic CpG island microarrays. PLOS ONE 4: e4830. doi:10.1371/
journal.pone.0004830. PubMed: 19283074.
24. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T (2006)
Chemical genomic screening for methylation-silenced genes in gastric
cancer cell lines using 5-aza-2'-deoxycytidine treatment and
oligonucleotide microarray. Cancer Sci 97: 64-71. doi:10.1111/j.
1349-7006.2006.00136.x. PubMed: 16367923.
BMP7 and Lymphoma
PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e73993
